切换导航
  • 比较产品
我的购物车

StemSpan™ T细胞祖细胞成熟添加物（10X）

促进淋巴祖细胞成熟为T细胞的添加物
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #09930_C

促进淋巴祖细胞成熟为T细胞的添加物

main product photo
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

StemSpan™ T细胞祖细胞成熟添加物（10X）支持淋巴祖细胞成熟为双阳性（DP）T细胞。

此添加物可单独购买，也可作为StemSpan™ T细胞生成试剂盒或STEMdiff™ T细胞试剂盒的一部分购买。在此试剂盒的实验方案中，首先使用StemSpan™淋巴祖细胞扩增添加物（10X）将CD34+ 细胞分化为CD7+ CD5+淋巴祖细胞，然后进一步分化为DP T 细胞。StemSpan ™ T细胞祖细胞成熟添加物（10X）旨在与StemSpan™ SFEM II培养基以及StemSpan™淋巴分化包被材料（100X）包被的培养板搭配使用。同时，该培养基可以通过额外的刺激支持DP T细胞成熟为CD8 T细胞。

有关StemSpan™扩增和分化CD34+细胞的详细方案，请参阅技术手册和相关材料。

亚型
添加剂
 
细胞类型
造血干/祖细胞
 
种属
人
 
应用
细胞培养，分化
 
品牌
StemSpan
 
研究领域
癌症，免疫，干细胞生物学，细胞治疗开发
 
制剂类别
无血清
 

查看更多 显示更少

Data Figures

Figure 1. Frequency and Yield of CD7+CD5+ Pro-T Cells After 14 Days of Culture

CB-derived CD34+ cells (freshly isolated or frozen) were cultured for 14 days in StemSpan™ SFEM II containing Lymphoid Progenitor Expansion Supplement (Catalog #09915) on plates coated with Lymphoid Differentiation Coating Material (Catalog #09925). Cells were harvested and analyzed for CD7 and CD5 expression by (A) flow cytometry. The (B) average frequency of viable CD7+CD5+ pro-T cells on day 14 was 70%, with ~200 CD7+CD5+ cells produced per input CD34+ cell. Shown are means with 95% confidence intervals (n = 33).

Figure 2. Frequency and Yield of CD4 ISP and CD4+CD8+ DP Cells After 42 Days of Culture

CB-derived CD34+ cells (freshly isolated or frozen) were cultured with the StemSpan™ T Cell Generation Kit (Catalog #09940) for 42 days and (A) analysed by flow cytometry for the expression of CD4, CD8, CD3 and TCRαβ. The (B) frequency and (C) yield of CD4 ISP, double-positive (CD4+CD8+) and CD3+TCRαβ+-expressing double-positive cells (CD4+CD8+CD3+TCRαβ+) are shown. On average, 38% of the total viable population were DP (CD4+CD8+), of which 35% co-expressed CD3 and TCRαβ. The yields of total DP cells and CD3+TCRαβ+ DP cells per input CD34+ cell were ~23,000 and ~9,000, respectively. Shown are means with 95% confidence intervals (n = 31).

Figure 3. Frequency and Yield of CD8 SP T Cells After 49 Days of Culture

DP cells were further matured into CD8 SP T cells by culturing for an additional 7 days in StemSpan™ SFEM II with T Cell Progenitor Maturation Supplement (Catalog #09930), IL-15 (Catalog #78031) and ImmunoCult™ CD3/CD28/CD2 T Cell Activator (Catalog #10970) on coated plates. On day 49, cells were (A) analyzed by flow cytometry for the expression of CD3, TCRαβ, CD4 and CD8. The (B) frequency and yield of CD3+TCRαβ+-expressing cells and their subsets are shown. On average, 54% of the CD3+TCRαβ+ cells were DP (CD4+CD8+) and 38% were CD8 SP (CD4-CD8+). The average yield of CD8 SP T cells per input CD34+ cell was ~6,000. CD3+TCRαβ+ CD4 SP (CD4+CD8-) T cells were detected at very low frequencies (data not shown). Shown are means with 95% confidence intervals (n = 12).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
StemSpan™ T Cell Progenitor Maturation Supplement (10X)
Catalog #
09930
Lot #
All
Language
English
Document Type
Technical Manual
Product Name
StemSpan™ T Cell Progenitor Maturation Supplement (10X)
Catalog #
09930
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
StemSpan™ T Cell Progenitor Maturation Supplement (10X)
Catalog #
09930
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages

更多信息

更多信息
Species Human
Formulation Category Serum-Free
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。